Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 1.0
IO Biotech, Inc. faced acceleration on loan of €22.5 million with European Investment Bank.
- Instrument
- loan
- Principal
- €22.5 million
- Counterparty
- European Investment Bank
- Event
- acceleration
Exact text from the filing
The appointment of the Chapter 7 trustee as described in Item 1.03 of this Current Report on Form 8-K triggers an event of default under the finance contract between the Company’ subsidiary IO Biotech ApS and the European Investment Bank (“EIB”) and provides EIB the right to terminate the finance contract and demand from the Company and IO Biotech ApS immediate repayment of the €22.5 million drawn under the finance contract together with accrued interest, prepayment fees and certain costs and expenses.
View on SEC.gov
Distress & Bankruptcy
SEC 8-K Item 1.03
confidence 0.9
IO Biotech, Inc. entered chapter 7 in United States Bankruptcy Court for the District of Delaware (petition 2026-03-31).
- Proceeding
- chapter 7
- Court
- United States Bankruptcy Court for the District of Delaware
- Petition
- 2026-03-31
Exact text from the filing
On March 31, 2026, after considering all strategic alternatives, IO Biotech, Inc. (the “Company”) ceased operations and filed a voluntary petition for relief (the “Petition”) under the provisions of Chapter 7 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”).
View on SEC.gov